GGrantIndex
Sort

48,018 grants matching immunotherapy

Mechanisms of liver metastasis and associated resistance to immunotherapy

$438,730
Benjamin Izar · Columbia University Health Sciences · R37 · FY2022 · CA

Immunoengineered nanotechnology for targeted expansion of regulatory T cells

$438,721
Jamie Berta Spangler · Johns Hopkins University · R01 · FY2020 · EB

Advancing T cell Therapy for Ovarian Cancer

$438,669
George Coukos · Fox Chase Cancer Center · P50 · FY2009 · CA

S100A4 mediated immune suppression in GBM

$438,652
Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2023 · NS

S100A4 mediated immune suppression in GBM

$438,652
Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2022 · NS

INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION

$438,581
Weill Medical College Of Cornell Univ · U01 · FY2001 · AI

Engineering Responsive Chemical Heterogeneity in Protein Vesicles for Simultaneous Delivery of Diverse Cargoes

$438,521
Julie Champion · Georgia Tech Research Corporation · · FY2021 · MPS

Dual-pronged nano-drug delivery using plant virus-like particles.

$438,466
Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2018 · CA

Crosslinking conjugates to localize and activate NK cells in glioblastoma

$438,452
Benjamin W. Purow · University Of Virginia · R21 · FY2019 · NS

A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding

$438,411
Evan Alexander Scott · Northwestern University · R01 · FY2022 · EB

A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding

$438,411
Evan Alexander Scott · Northwestern University · R01 · FY2023 · EB

Inner City Asthma consortium 3 (ICAC3)

$438,405
Daniel J Jackson · University Of Wisconsin-Madison · UM1 · FY2020 · AI

Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma

$438,385
Christopher Austin Klebanoff · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Chemotherapy plus vaccine for metastatic breast cancer

$438,356
Johns Hopkins University · R01 · FY2005 · CA

Microenvironmental Influences in Cancer

$438,353
Jin Chen · Vanderbilt University · T32 · FY2021 · CA

Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment

$438,296
Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Clinical implementation of single cell tumor transcriptome analysis

$438,255
Aviv Regev · Broad Institute, Inc. · R33 · FY2017 · CA

Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets

$438,083
Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2023 · CA

Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy

$438,076
Guillermo N Armaiz-Pena · Ponce School Of Medicine · R21 · FY2020 · CA

Resource for Nonhuman Primate Immune Reagents

$437,988
Francois J Villinger · University Of Louisiana At Lafayette · R24 · FY2022 · OD

Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T

$437,922
David A Scheinberg · Sloan-Kettering Inst Can Research · P01 · FY2014 · CA

Radiotherapy as Immunotherapy of Tumors

$437,914
Samuel Strober · Stanford University · R01 · FY2016 · CA

Radiotherapy as Immunotherapy of Tumors

$437,914
Samuel Strober · Stanford University · R01 · FY2015 · CA

Radiotherapy as Immunotherapy of Tumors

$437,914
Samuel Strober · Stanford University · R01 · FY2012 · CA

MEDICINE ENHANCED IMMUNOTHERAPY AND TARGETED THERAPY FOR NON SMALL CELL LUNG CANCER

$437,906
Brigham & Womens Hospital Inc · · FY2025 · Defense Health Agency